Q2 2024 EPS Estimates for Celldex Therapeutics, Inc. Increased by Leerink Partnrs (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Stock analysts at Leerink Partnrs raised their Q2 2024 EPS estimates for Celldex Therapeutics in a research note issued on Monday, May 6th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical company will earn ($0.51) per share for the quarter, up from their prior forecast of ($0.69). The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.85) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.62) EPS, FY2024 earnings at ($2.22) EPS, FY2025 earnings at ($2.84) EPS, FY2026 earnings at ($3.70) EPS, FY2027 earnings at ($3.56) EPS and FY2028 earnings at $1.53 EPS.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The company had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $1.20 million.

Several other equities analysts have also recently issued reports on the company. Guggenheim lifted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Friday, March 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Celldex Therapeutics Trading Down 2.4 %

NASDAQ:CLDX opened at $41.21 on Thursday. The stock has a fifty day moving average price of $41.71 and a 200 day moving average price of $37.03. Celldex Therapeutics has a 12-month low of $22.11 and a 12-month high of $53.18. The firm has a market cap of $2.30 billion, a PE ratio of -14.16 and a beta of 1.60.

Institutional Trading of Celldex Therapeutics

Several institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC grew its position in shares of Celldex Therapeutics by 70.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 805 shares during the last quarter. Strs Ohio grew its position in Celldex Therapeutics by 92.9% during the 4th quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 1,300 shares during the last quarter. Headlands Technologies LLC acquired a new position in Celldex Therapeutics in the first quarter valued at $147,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Celldex Therapeutics by 36.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,582 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 1,746 shares during the last quarter. Finally, Aigen Investment Management LP acquired a new position in Celldex Therapeutics in the 4th quarter valued at about $251,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.